Output details

¹⁸F-fluoride PET as a non-invasive imaging biomarker for determining treatment efficacy of bone active agents at the hip : A prospective, randomised, controlled clinical study

Lead investigator of first randomized, controlled clinical trial demonstrating 18F-fluoride PET as an early non-invasive imaging biomarker of treatment efficacy at the hip. This has not been possible previously, and is important due to the profound individual and socio-economic impact of hip fractures, along with the recent acceleration of development of bone-active agents that are efficacious at the hip. Our technique overcomes the limitations of conventional methods and has since been adopted by Novartis Pharma in their drug development programme as a biomarker for a Phase II trial of a novel anabolic bone therapy in patients with chronic kidney disease.